Takeaway

• In patients with stage II colon cancer, an approach based on circulating tumour DNA (ctDNA) reduces the use of adjuvant chemotherapy without compromising recurrence risk.
• ctDNA-positive patients are likely to benefit from adjuvant chemotherapy, while ctDNA-negative patients are not.

Why this matters

• Surgery can cure more than 80% of...